Clinical Trial Update: Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of semaglutide for alcohol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Alcohol Use Disorder | Phase 3 | Status: NOT_YET_RECRUITING